OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) Chemical Structure

Molecular Weight(MW): 421.49

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Cancer Res 2013 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck.

  •  

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    OSI-906 (Linsitinib) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
35 nM 75 nM 75 nM >10 μM >10 μM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NGXLdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEK4NFYh|ryP MUHTRW5ITVJ?
KS-1 NGjLUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX0R3c2UUN3ME2wMlA{QDN3IN88US=> MWnTRW5ITVJ?
TE-11 NYnKfIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TJ[GlEPTB;MD6wO|gzOiEQvF2= NUfBUpR2W0GQR1XS
EW-1 M3;XfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\qcGlEPTB;MD6wPFU5PSEQvF2= NEfwbVNUSU6JRWK=
HMV-II Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEi4OFYh|ryP NXnkXHFIW0GQR1XS
COLO-205 NX\hRlk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD1yLkGwOFU1KM7:TR?= MV3TRW5ITVJ?
ES1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWXJlKSzVyPUCuNVA3QTZizszN MYPTRW5ITVJ?
GDM-1 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjtcnBGUUN3ME2wMlE{Pjd{IN88US=> NV3yVoJVW0GQR1XS
ML-2 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPydYRKSzVyPUCuNVU5QTZizszN NV3h[lZwW0GQR1XS
Saos-2 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMU[1NlYh|ryP M3;nbnNCVkeHUh?=
NCI-H1355 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXUXlM6UUN3ME2wMlE5OTN3IN88US=> NES1ZZFUSU6JRWK=
G-401 M3LmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPaXJoxUUN3ME2wMlE5OjNizszN NY\lWXllW0GQR1XS
EW-16 NV74Z2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXweIxCUUN3ME2wMlE5Pzd5IN88US=> M2OxZ3NCVkeHUh?=
EW-7 M3XY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzyR3NKSzVyPUCuNVg5QDFizszN NW\nToVmW0GQR1XS
NCI-H727 NUHnOpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMUm3PVQh|ryP MlzHV2FPT0WU
LCLC-97TM1 NHzx[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXryNYJCUUN3ME2wMlIxQTV3IN88US=> Ml7rV2FPT0WU
NCI-H650 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvVellKSzVyPUCuNlE{QDRizszN M2nhUHNCVkeHUh?=
NCI-H2122 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHXfHZKSzVyPUCuNlMzQTlizszN M4jiO3NCVkeHUh?=
SK-N-DZ MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruV4xKSzVyPUCuNlM3QThizszN NILtPW9USU6JRWK=
HT-29 NY\EeVRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMkSyOFgh|ryP MXfTRW5ITVJ?
LB771-HNC NIf3W|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TMR2lEPTB;MD6yOVkyPSEQvF2= NHXQZpZUSU6JRWK=
HT-144 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPHelJHUUN3ME2wMlI3OTlzIN88US=> M4XhVnNCVkeHUh?=
LAN-6 M{PBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET6[4lKSzVyPUCuNlY{PDhizszN MlXVV2FPT0WU
EW-18 M{PPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCwTWM2OD1yLkK3NFAyKM7:TR?= M4rSOnNCVkeHUh?=
LS-1034 NX3MepZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf6TWM2OD1yLkK3NVMzKM7:TR?= NVOyR21YW0GQR1XS
EW-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGyd|hvUUN3ME2wMlI5PDN{IN88US=> NEXpW4VUSU6JRWK=
SNU-C1 MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\HU4tyUUN3ME2wMlI6OzF|IN88US=> MmnSV2FPT0WU
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDvTWM2OD1yLkOzO|U5KM7:TR?= MV7TRW5ITVJ?
ES4 M3zl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rJe2lEPTB;MD60NVA{QCEQvF2= NIn6VoVUSU6JRWK=
COLO-320-HSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS5TWM2OD1yLkSxN|Y5KM7:TR?= MXPTRW5ITVJ?
NB10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1THcWlEPTB;MD60OVQ{PyEQvF2= Ml3zV2FPT0WU
BFTC-905 M1\ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPEfohKSzVyPUCuOFY4PThizszN NF3tPG9USU6JRWK=
A375 NI\4ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n4TGlEPTB;MD60O|YyPyEQvF2= NHfC[lFUSU6JRWK=
SJRH30 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnWfVB2UUN3ME2wMlUxQDJ{IN88US=> Mn3lV2FPT0WU
NOS-1 NF74UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr5TWM2OD1yLkWyNlY4KM7:TR?= M3foc3NCVkeHUh?=
SIG-M5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\EPIRKSzVyPUCuOVM2PTdizszN MXXTRW5ITVJ?
DOK NG[5dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PNNWlEPTB;MD61OVYh|ryP Ml7YV2FPT0WU
NB69 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r3U2lEPTB;MD61PFI2PyEQvF2= NF3s[XJUSU6JRWK=
SK-NEP-1 M371XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1yLk[wNlM3KM7:TR?= M37SXnNCVkeHUh?=
SK-MM-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm2TWM2OD1yLk[1OFkyKM7:TR?= MV3TRW5ITVJ?
NCI-H358 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknsTWM2OD1yLk[3NFgzKM7:TR?= MnfiV2FPT0WU
RH-1 NV;jepJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojqTWM2OD1yLke0PFU6KM7:TR?= Moq2V2FPT0WU
NH-12 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwN{[wOFYh|ryP M2X1cHNCVkeHUh?=
TE-12 NEDaOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfzTWM2OD1yLke2OFg3KM7:TR?= M{CwbnNCVkeHUh?=
COLO-668 NX\zNmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3ZlB5UUN3ME2wMlg1PjZ4IN88US=> NV7rToRqW0GQR1XS
PANC-08-13 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwOE[zO|ch|ryP MojFV2FPT0WU
HCC2998 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwOEiyOlMh|ryP MoS3V2FPT0WU
ABC-1 NFP4emhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwOUCzOVIh|ryP MYTTRW5ITVJ?
ES6 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;LbWlEPTB;MD65NVA3PiEQvF2= NH\rT4dUSU6JRWK=
SNU-387 NXjnS4dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jmXWlEPTB;MD65PVM6OyEQvF2= NW\FUmlXW0GQR1XS
CMK NVfjSFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;uTWM2OD1yLkm5PVI6KM7:TR?= NEfncIxUSU6JRWK=
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrPS3VKSzVyPUGuNFM3PTNizszN NYXmWWZEW0GQR1XS
SIMA MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\xW|lrUUN3ME2xMlA3QDJ3IN88US=> NF;6fo5USU6JRWK=
ES3 NXjVTIU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n1VWlEPTB;MT6xNlI6PyEQvF2= Ml\RV2FPT0WU
IGROV-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTwTWM2OD1zLkG1OFQ1KM7:TR?= NXq3bG9yW0GQR1XS
MEL-JUSO NGPBT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\yeGlEPTB;MT6xOVc2QSEQvF2= NXTtXYVuW0GQR1XS
T84 NX\SRph4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jmXmlEPTB;MT6yNFkyPCEQvF2= NUewWm53W0GQR1XS
CAL-85-1 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\RTWM2OD1zLkKzNVM5KM7:TR?= MlrvV2FPT0WU
RD NIfmZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPTT|RKSzVyPUGuNlY1PTVizszN MlXDV2FPT0WU
TE-8 NGDnO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjabWZlUUN3ME2xMlMyPDZ{IN88US=> MV;TRW5ITVJ?
L-363 M4jNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X4bWlEPTB;MT6zOFIxQCEQvF2= MlTkV2FPT0WU
EKVX MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwM{S1Olgh|ryP Ml\4V2FPT0WU
SK-MEL-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTF[49KSzVyPUGuOFg2PTZizszN NFizRXpUSU6JRWK=
TGBC24TKB NUfNdJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\vOppmUUN3ME2xMlUxOTl|IN88US=> NVW0VGZIW0GQR1XS
NCI-H1770 M4DhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwNUGxNVMh|ryP NV\rbm81W0GQR1XS
HuH-7 NYj6b|BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojuTWM2OD1zLk[wNFk5KM7:TR?= M3XRc3NCVkeHUh?=
HL-60 NGfqcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KxWWlEPTB;MT62OlkzQCEQvF2= NF20SpNUSU6JRWK=
TE-1 M3rOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i1S2lEPTB;MT63NFk1PSEQvF2= NW\mNIFbW0GQR1XS
LC-2-ad NW\rPGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX5TWM2OD1zLkezPFg4KM7:TR?= NWXpbHZoW0GQR1XS
LB647-SCLC MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPRZ25TUUN3ME2xMlc3PTh|IN88US=> NG\W[GRUSU6JRWK=
NCI-H2171 NV\aOml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfITWM2OD1zLke3O|E3KM7:TR?= NILaXIlUSU6JRWK=
SK-PN-DW MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG5fplKSzVyPUGuPVEzQThizszN Ml7mV2FPT0WU
MC-IXC M2HZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDnNpRKSzVyPUGuPVg6QCEQvF2= MmmzV2FPT0WU
LS-513 M3PsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XtVWlEPTB;Mj6wOVMxPSEQvF2= MYjTRW5ITVJ?
EW-3 NWjiUm9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlezTWM2OD1{LkC5PFQ1KM7:TR?= NHTrUpFUSU6JRWK=
OPM-2 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJwMUCyJO69VQ>? NHrKZm5USU6JRWK=
LP-1 NGjYRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwMkW4NFch|ryP NXL3TGlqW0GQR1XS
LU-134-A MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn5emlFUUN3ME2yMlI4PyEQvF2= NX\UbFZoW0GQR1XS
CP66-MEL NXXwUJhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvObI1EUUN3ME2yMlI6ODF2IN88US=> NH7Qc4RUSU6JRWK=
HCC1143 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHMTWM2OD1{LkS1N|Y5KM7:TR?= MYLTRW5ITVJ?
LOXIMVI NXfIUXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nzS2lEPTB;Mj62NFIyKM7:TR?= M4PTc3NCVkeHUh?=
TE-10 NV3OVndJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwN{C4N|gh|ryP NEG1SJdUSU6JRWK=
NCI-H1882 NXTFfIlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vnb2lEPTB;Mj63OVIzPyEQvF2= NEjYN5NUSU6JRWK=
CHP-126 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe4T3pKSzVyPUKuO|Y{OTdizszN MWXTRW5ITVJ?
NCI-H1623 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO0ZZRKSzVyPUKuPVIxOjRizszN NYX2TmZtW0GQR1XS
GB-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mzfmlEPTB;Mj65N|QxPCEQvF2= NUnERmFOW0GQR1XS
RCC10RGB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16wVGlEPTB;Mj65OVI5OSEQvF2= NIOyNpZUSU6JRWK=
NCI-H2141 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7XOFZKSzVyPUKuPVY5QTZizszN Mlj4V2FPT0WU
GI-ME-N M2HoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP2[nBKSzVyPUOuNFA2PjVizszN Ml\SV2FPT0WU
NCI-H526 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojWTWM2OD1|LkC0NFg2KM7:TR?= NYrDdJV4W0GQR1XS
NCI-H747 NH;TfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T3U2lEPTB;Mz6wOFk6OiEQvF2= MV;TRW5ITVJ?
SNU-423 NH;zN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPBTWM2OD1|LkKwN|E{KM7:TR?= NXz1Uo94W0GQR1XS
A427 NIjZdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D4emlEPTB;Mz6yOVY6QSEQvF2= NF31TohUSU6JRWK=
CAL-12T M1P5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj1TWM2OD1|LkSwO|E{KM7:TR?= MUjTRW5ITVJ?
LU-99A M{fmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPSSZViUUN3ME2zMlQ4OTB3IN88US=> MnrlV2FPT0WU
MS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjMdVFpUUN3ME2zMlU{PDJ7IN88US=> MW\TRW5ITVJ?
SK-LU-1 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLuTWM2OD1|Lke2Nlk2KM7:TR?= M{Xa[XNCVkeHUh?=
SW837 NFyxdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XGRWlEPTB;Mz63OlM{OyEQvF2= M2W0W3NCVkeHUh?=
ES8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj1[ZFKSzVyPUOuPFM5PzdizszN NYT1ZYMzW0GQR1XS
MZ2-MEL NUf3UXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTzN|BKSzVyPUOuPVIxQDZizszN M3LXWnNCVkeHUh?=
TGW M1njWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDlTWM2OD12LkCxN|EyKM7:TR?= MVzTRW5ITVJ?
GP5d M4Ta[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HPPWlEPTB;ND6wOVM3OiEQvF2= M1;zO3NCVkeHUh?=
BB49-HNC NGXIdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD12LkG1NlE{KM7:TR?= MnzIV2FPT0WU
NB13 M1[xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;FO21nUUN3ME20MlI3QDh5IN88US=> MnTqV2FPT0WU
NTERA-S-cl-D1 NEnmRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M361cmlEPTB;ND6yPFYyPSEQvF2= M2TSO3NCVkeHUh?=
NCI-H1648 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\5e4lKUUN3ME20MlI6QDF7IN88US=> M{S4SXNCVkeHUh?=
LCLC-103H M2fLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRwM{KxPVUh|ryP MWLTRW5ITVJ?
LS-411N NYPl[HZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XvZmlEPTB;ND60OFg5PSEQvF2= MmjjV2FPT0WU
NCI-H1092 M1\nV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXZfWlKSzVyPUSuOFU3QDdizszN MljqV2FPT0WU
PANC-10-05 NULz[ZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTRwNkm4OEDPxE1? M3zs[XNCVkeHUh?=
DK-MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPEVFNZUUN3ME20MlgxQTN|IN88US=> NI\NO|BUSU6JRWK=
OVCAR-5 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRwOEGyNlYh|ryP Mn;1V2FPT0WU
CAL-39 NV7UXlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXxUpU6UUN3ME20Mlg4PjdizszN NYnOSpZLW0GQR1XS
TE-441-T NHO4e2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTRwOUC1N|ch|ryP NFHwZ5ZUSU6JRWK=
MOLT-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXITWM2OD12Lkm1NlU{KM7:TR?= NF3wRZhUSU6JRWK=
MCF7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPnWG5KUUN3ME21MlE1PTF5IN88US=> Mnv5V2FPT0WU
CAPAN-1 NGLvcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nxRWlEPTB;NT6yOVcxPyEQvF2= M1jUfnNCVkeHUh?=
PSN1 NWq2[YdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwMkeyN|Uh|ryP MYDTRW5ITVJ?
NCI-H292 NFmzOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwM{CwOFQh|ryP M2DRSnNCVkeHUh?=
CPC-N NGTLXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq5RW5SUUN3ME21MlM6PDF7IN88US=> NUTKOJU{W0GQR1XS
DoTc2-4510 NYHHPW9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVwNEWzO|Eh|ryP NFjxVXlUSU6JRWK=
LB1047-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fRTmlEPTB;NT61OVk{OyEQvF2= NIrNO41USU6JRWK=
MHH-ES-1 M3XGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;2THpKSzVyPUWuOVk6ODdizszN M17lSHNCVkeHUh?=
NMC-G1 NHTvPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle5TWM2OD13LkewNlI4KM7:TR?= M1G0V3NCVkeHUh?=
SW1710 NHzPU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\GO2lEPTB;NT63OFc2OSEQvF2= NFLvUJdUSU6JRWK=
YAPC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwN{[yNFEh|ryP M2TyVXNCVkeHUh?=
22RV1 NH7JZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[yR4dKSzVyPUWuPFAxOTlizszN NFiwN|FUSU6JRWK=
COLO-679 NHK4WXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD13Lki4PVQ5KM7:TR?= NInDU4JUSU6JRWK=
TCCSUP NV3TPWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTVfFBkUUN3ME21Mlk{OjV7IN88US=> NELRelJUSU6JRWK=
C2BBe1 M4fIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLJW|IyUUN3ME21Mlk{QTdizszN M1fOVHNCVkeHUh?=
TE-15 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWxTWM2OD14LkC2OlA2KM7:TR?= MkLzV2FPT0WU
SCLC-21H NFXDOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4O5hKSzVyPU[uNVA5PDNizszN Mk[xV2FPT0WU
EoL-1-cell MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwMU[1OlMh|ryP NGO5dG5USU6JRWK=
NKM-1 NIjh[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq2TGdKSzVyPU[uNVY4OSEQvF2= M{PTOXNCVkeHUh?=
NCI-H1304 M1XlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DVemlEPTB;Nj6yO|QzQCEQvF2= M1;qNHNCVkeHUh?=
NB6 NYT1cnVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLXdXhUUUN3ME22MlI6PjJ{IN88US=> Mor0V2FPT0WU
NALM-6 NFTCNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQWoo6UUN3ME22MlM{OjNizszN NELod2RUSU6JRWK=
NCI-H522 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\0fmN5UUN3ME22MlM{OzB4IN88US=> MWLTRW5ITVJ?
MV-4-11 MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrGTWM2OD14LkO3NFc6KM7:TR?= NYnRb4tUW0GQR1XS
LB2241-RCC MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwM{i2Olch|ryP M4ftc3NCVkeHUh?=
NCI-H1417 NHTD[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDqTWM2OD14LkSwPFQ4KM7:TR?= M135V3NCVkeHUh?=
HT-1197 NXXWVHFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTZwNUexNlIh|ryP MnS2V2FPT0WU
P30-OHK MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITrT4pKSzVyPU[uOlI4PyEQvF2= NIfWSWVUSU6JRWK=
ALL-PO NYPGU3BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;KTWM2OD14LkexPVE3KM7:TR?= NUOyPIFyW0GQR1XS
OVCAR-4 NYTqcIE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zjbmlEPTB;Nj63OVQxPSEQvF2= MXvTRW5ITVJ?
HCC2157 NH7Ee3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZwN{e0O|Uh|ryP NEPWZ2tUSU6JRWK=
NCI-H838 M33INGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLYTWM2OD14Lkm2OFkh|ryP NWPjT2dZW0GQR1XS
NCI-H1299 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwOUewPUDPxE1? NYrjfWF[W0GQR1XS
SW954 NXzwS4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTdwMkCwOlgh|ryP MmG1V2FPT0WU
NCI-H441 NFvOelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\FZWlEPTB;Nz6zOFA3PSEQvF2= NWjsenJmW0GQR1XS
SK-MEL-2 NGHJelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;0VZpKSzVyPUeuOFg{PzNizszN NVfRSWNYW0GQR1XS
KARPAS-45 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTdwNkW5Nlkh|ryP MkSwV2FPT0WU
CAL-54 NIXDNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjrPJZKSzVyPUeuPFI6PzdizszN MXrTRW5ITVJ?
KYSE-180 M{L0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[xRWJKSzVyPUeuPFg6PDFizszN MnrRV2FPT0WU
NCI-H187 M2T1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTdwOUW5OFch|ryP M1rEVXNCVkeHUh?=
RT-112 M1f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV74fJVPUUN3ME24MlA6Pjd5IN88US=> M4rVS3NCVkeHUh?=
NCI-H1437 M4P2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ze2lEPTB;OD6wPVc6PSEQvF2= MWHTRW5ITVJ?
SNU-449 M17KR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\hbllvUUN3ME24MlI5Ojd{IN88US=> M3j3RnNCVkeHUh?=
HCC1187 M2jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzmdGV{UUN3ME24MlI6OzlzIN88US=> NIrJT|ZUSU6JRWK=
NCI-H2030 NG\ldFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO0V2VKSzVyPUiuN|c4OTRizszN NEjFVZRUSU6JRWK=
HuO-3N1 NH3UcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\STGZDUUN3ME24MlM4QDR2IN88US=> NXLMd5JKW0GQR1XS
COLO-792 NH3wUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vBdGlEPTB;OD60NVUzPyEQvF2= MnXKV2FPT0WU
MIA-PaCa-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzp[4tKUUN3ME24Mlg2PTB6IN88US=> NWfaPYFWW0GQR1XS
SK-N-FI NHy5VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTlwMESyOUDPxE1? MXLTRW5ITVJ?
MMAC-SF NGWxVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjPTWM2OD17LkC5O|UyKM7:TR?= Mk\OV2FPT0WU
NCI-H28 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnRboVjUUN3ME25MlExPDZ7IN88US=> MVTTRW5ITVJ?
ETK-1 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTlwMkm5O|Qh|ryP NHG4fVNUSU6JRWK=
NCI-H1993 NVHBVGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ENG4yUUN3ME25MlQ1OjZzIN88US=> M2TUe3NCVkeHUh?=
no-11 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkWWlEPTB;OT60O|EzKM7:TR?= MoLRV2FPT0WU
ChaGo-K-1 M1vsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTlwNUG1PFMh|ryP MV7TRW5ITVJ?
NCCIT NFvhOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTlwNUOxOlkh|ryP M2PIZXNCVkeHUh?=
SAS M1fH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFyLkK0PEDPxE1? MWrTRW5ITVJ?
A673 M{\NOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rBcWlEPTB;MUCuN|cxPCEQvF2= NGXBU5hUSU6JRWK=
NCI-H1522 NUi5Rnk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHhdotKSzVyPUGwMlM4ODdizszN MX\TRW5ITVJ?
NCI-H810 NUDjW3Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTxd4p7UUN3ME2xNE4{QTB5IN88US=> MWXTRW5ITVJ?
IST-MES1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjLeWEyUUN3ME2xNE41PTZ2IN88US=> NYfuXmVUW0GQR1XS
GR-ST MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v1[mlEPTB;MUCuOVAzPCEQvF2= MX3TRW5ITVJ?
SUP-T1 M{\zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorITWM2OD1zMD63N|E4KM7:TR?= NES1Z5ZUSU6JRWK=
NB5 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfOTWM2OD1zMD65NFIzKM7:TR?= M4DW[XNCVkeHUh?=
MZ1-PC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHwTYdHUUN3ME2xNE46PTdzIN88US=> M4DTfHNCVkeHUh?=
SK-CO-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKwTWM2OD1zMD65PVMyKM7:TR?= NIPXe4ZUSU6JRWK=
Capan-2 NXTQPGxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M363bWlEPTB;MUGuN|E6QCEQvF2= M4DKbHNCVkeHUh?=
697 NVj0bWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL5TWM2OD1zMT62O|U4KM7:TR?= M2nmS3NCVkeHUh?=
REH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGXJZNUUN3ME2xNU44PDVzIN88US=> M1PaUXNCVkeHUh?=
GI-1 M3\3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSzclhKSzVyPUGxMlg3OTVizszN NG[zc|FUSU6JRWK=
BB65-RCC Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLlTWM2OD1zMj6wPVE3KM7:TR?= NUXLUXZjW0GQR1XS
NCI-H1651 NIXVcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF{LkK0O|gh|ryP NX3Fd2Y5W0GQR1XS
NCI-H1618 M1ezU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF{LkO5O|Yh|ryP NE\RUm5USU6JRWK=
NCI-H2081 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Die2lEPTB;MUKuOlE1OSEQvF2= NHXmZY5USU6JRWK=
GCIY MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnLXmtEUUN3ME2xNk44OjF|IN88US=> M{OybXNCVkeHUh?=
NY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ycWlEPTB;MUOuNFY1OyEQvF2= MVnTRW5ITVJ?
PANC-03-27 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF|LkC4NFch|ryP MXPTRW5ITVJ?
BHY NXy2ZoN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Lc2lEPTB;MUOuNlEzOSEQvF2= M1vyenNCVkeHUh?=
SK-OV-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PnUmlEPTB;MUOuN|c3OyEQvF2= NXHFVVRiW0GQR1XS
5637 NFPU[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXDfZJKSzVyPUGzMlc4PTlizszN M3jscHNCVkeHUh?=
LC-1F M{nPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzveGNKSzVyPUG0MlA{PTZizszN M{TuRnNCVkeHUh?=
SNB75 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\DTWM2OD1zND6wN|g{KM7:TR?= MlL4V2FPT0WU
CHP-212 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjtbmdKSzVyPUG0MlA1PjRizszN MX7TRW5ITVJ?
HT-1376 M4\mcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jrTWlEPTB;MUSuNVEzPiEQvF2= NYjvR3YzW0GQR1XS
MONO-MAC-6 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTt[WhCUUN3ME2xOE4yPTB{IN88US=> MWTTRW5ITVJ?
CA46 M3fhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH72UIJKSzVyPUG0MlE5OjdizszN Mlz6V2FPT0WU
SCC-15 NF7IO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wV3pQUUN3ME2xOE42PTh|IN88US=> Ml;RV2FPT0WU
ATN-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqyTWM2OD1zND62OlI4KM7:TR?= Mon6V2FPT0WU
NCI-H2405 NEHIcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nS[mlEPTB;MUSuPFE2PyEQvF2= NGDsdVdUSU6JRWK=
NCI-H716 M1fiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[wTWM2OD1zND64OFk{KM7:TR?= NXzKPIVlW0GQR1XS
SW620 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjnXWIyUUN3ME2xOE46ODF2IN88US=> MVvTRW5ITVJ?
NCI-H226 M{TxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDIWWZKSzVyPUG0MlkxQDVizszN M3nNc3NCVkeHUh?=
SW962 NV:0NXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki5TWM2OD1zND65OFMzKM7:TR?= MYHTRW5ITVJ?
KYSE-150 NHLsZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jM[GlEPTB;MUSuPVU2KM7:TR?= M3SwTHNCVkeHUh?=
OCUB-M MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nUcWlEPTB;MUSuPVg5OyEQvF2= M2W1Z3NCVkeHUh?=
ES7 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O3W2lEPTB;MUWuNFk5PCEQvF2= M{[4[nNCVkeHUh?=
SW1463 M1rv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDnOIJKSzVyPUG1MlQzOjNizszN MWjTRW5ITVJ?
CAKI-1 NUW2bFRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XRU2lEPTB;MUWuOVM1PiEQvF2= NYjvV2d5W0GQR1XS
MKN28 NXq3eG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETNZVZKSzVyPUG1MlU1PzlizszN NIrJN|FUSU6JRWK=
SW13 NVqwfIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe2bpNYUUN3ME2xOU43OThizszN M1W1N3NCVkeHUh?=
A3-KAW Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P4SWlEPTB;MUWuPVY6PyEQvF2= MYnTRW5ITVJ?
LU-65 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF3Lkm3Olgh|ryP NXLXVmFxW0GQR1XS
Calu-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHwWppbUUN3ME2xOk4xOzZ6IN88US=> MYXTRW5ITVJ?
ST486 M3W5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG0XHlKSzVyPUG2MlA1OzFizszN MWHTRW5ITVJ?
BB30-HNC MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rib2lEPTB;MU[uNVI1PiEQvF2= MnW1V2FPT0WU
EGI-1 NF35OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxNmJKSzVyPUG2MlQ1PiEQvF2= MoTTV2FPT0WU
SH-4 NGLCb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[4TmlEPTB;MU[uOFc{OSEQvF2= Mmr2V2FPT0WU
MN-60 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF5LkKyPVch|ryP MWDTRW5ITVJ?
MPP-89 NIHnfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF5LkK0OVkh|ryP MYTTRW5ITVJ?
A2780 NU\wZXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jGTGlEPTB;MUeuOFE{QSEQvF2= Mn;YV2FPT0WU
Daoy M4r2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOV5JZUUN3ME2xO{41Pjl3IN88US=> NET5b|BUSU6JRWK=
NCI-H2126 NU\WZ4E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfUTWM2OD1zNz60O|cyKM7:TR?= MV\TRW5ITVJ?
NCI-H1563 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzpTWM2OD1zNz60PVE4KM7:TR?= MYHTRW5ITVJ?
8-MG-BA M3H3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPVTWM2OD1zNz62OlQ5KM7:TR?= MkS2V2FPT0WU
786-0 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH2TWM2OD1zNz64N|U{KM7:TR?= NVvwS3NsW0GQR1XS
AM-38 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGxS4kxUUN3ME2xO{46OzB4IN88US=> M2O1PHNCVkeHUh?=
COLO-824 MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnwdFNWUUN3ME2xPE41PDN4IN88US=> MmTjV2FPT0WU
SK-MEL-30 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF6LkWwPFIh|ryP NYDFS3pVW0GQR1XS
CESS NFjkWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF6Lke2NFkh|ryP NHziSWNUSU6JRWK=
BL-70 NH;4bWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjNXpppUUN3ME2xPE45OTV4IN88US=> MmT0V2FPT0WU
NCI-H2170 NEDmXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfrcZQxUUN3ME2xPE46OTd7IN88US=> MnfTV2FPT0WU
HT-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2ZmlEPTB;MUiuPVg{KM7:TR?= MorpV2FPT0WU
BOKU MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LxbmlEPTB;MUmuNFM5OSEQvF2= MoLNV2FPT0WU
HPAF-II M{WwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C0RmlEPTB;MUmuN|AyPSEQvF2= M4jwc3NCVkeHUh?=
KGN NXKzOY84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjwfmJKSzVyPUG5MlQ4PjVizszN MUnTRW5ITVJ?
MC-CAR NYPWd2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS2T2pDUUN3ME2xPU43OzF|IN88US=> NI[3VIVUSU6JRWK=
BHT-101 NGjreWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\vTWM2OD1zOT63O|ch|ryP NITIdGZUSU6JRWK=
SW1783 M1n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTjbYhKSzVyPUG5Mlc5ODZizszN MWHTRW5ITVJ?
KP-N-YN MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH1NppKSzVyPUKwMlAzPjJizszN Mn2xV2FPT0WU
LU-165 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJyLkW1O|Eh|ryP MXjTRW5ITVJ?
GOTO NYK0WHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HQ[2lEPTB;MkCuOlQ2OSEQvF2= M{Hk[XNCVkeHUh?=
EFM-19 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zaWmlEPTB;MkGuNFcyPiEQvF2= MnXaV2FPT0WU
CTV-1 NFv1UFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjjTWM2OD1{MT6xNFU1KM7:TR?= MnTPV2FPT0WU
HEL NUXzVoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\CdFdzUUN3ME2yNU41OjF4IN88US=> NV;aV4o3W0GQR1XS
SNU-C2B MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fxVGlEPTB;MkGuOFI3KM7:TR?= NE\RV4dUSU6JRWK=
ECC4 M4rqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7H[nlpUUN3ME2yNU44ODdizszN NGGyOYZUSU6JRWK=
NEC8 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTOXHlKSzVyPUKxMlg{PjhizszN M3L1U3NCVkeHUh?=
KMOE-2 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHmRVFKSzVyPUKxMlg6OjFizszN NY\BZoJ2W0GQR1XS
NCI-H524 NHjjcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX76TWNLUUN3ME2yNk4xQDB6IN88US=> NUL4bHFMW0GQR1XS
WSU-NHL MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJ{LkG1O|ch|ryP M2XmWXNCVkeHUh?=
SF126 NXjvZVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:2TWM2OD1{Mj6yOFY6KM7:TR?= NH;ZWnNUSU6JRWK=
HOP-92 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W4c2lEPTB;MkKuN|E3PyEQvF2= MVLTRW5ITVJ?
CTB-1 NVyy[ZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LUPWlEPTB;MkKuOFY4PyEQvF2= MV7TRW5ITVJ?
KYSE-270 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DLWGlEPTB;MkKuPVM2PyEQvF2= M{nQb3NCVkeHUh?=
SK-MEL-24 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISybndKSzVyPUKzMlE5PyEQvF2= NYLBXJh{W0GQR1XS
Calu-3 NI\WcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ|LkKxNlgh|ryP MXLTRW5ITVJ?
GAMG Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ|LkKzOlch|ryP MWrTRW5ITVJ?
SW1573 NFfw[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfEfG9KSzVyPUKzMlc1OTVizszN MlLYV2FPT0WU
MHH-NB-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ2LkCxPVQh|ryP NVXDc5VzW0GQR1XS
TK10 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ2LkWwNVMh|ryP NX3Yc4p[W0GQR1XS
LB373-MEL-D NVrUSYxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSxeXpKSzVyPUK0MlYxPjRizszN NX3CVmRRW0GQR1XS
KALS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHyTWM2OD1{ND63N|I4KM7:TR?= NUe3NpJiW0GQR1XS
HUTU-80 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDiTWM2OD1{NT64NFMzKM7:TR?= NHG2bplUSU6JRWK=
HuP-T3 NULxRVZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDhZm9KSzVyPUK2MlE3PzRizszN MkK0V2FPT0WU
OE19 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLnTWM2OD1{Nj6yNVU{KM7:TR?= Mn7xV2FPT0WU
J82 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjxTWM2OD1{Nj6yOFcyKM7:TR?= MnX5V2FPT0WU
DU-4475 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjHTWM2OD1{Nj6zPFE6KM7:TR?= MkXhV2FPT0WU
DMS-53 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;MdmlEPTB;Mk[uOVE{QCEQvF2= MYjTRW5ITVJ?
COLO-741 NX\6PIdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPLNGZVUUN3ME2yOk45OzR2IN88US=> NGnxeolUSU6JRWK=
SW48 M{fJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QTGlEPTB;Mk[uPFgzKM7:TR?= M1[3SXNCVkeHUh?=
IGR-1 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ4LkmzN|Qh|ryP NUL6RXJYW0GQR1XS
639-V NV\yRYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITyNWZKSzVyPUK3MlAzPDVizszN NITNXWJUSU6JRWK=
LK-2 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;mbXdKSzVyPUK3MlQyPDFizszN MlroV2FPT0WU
NCI-H2347 M{faW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfOUItKSzVyPUK3Mlk3QTlizszN NGjNW49USU6JRWK=
NCI-H2228 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrZWZh6UUN3ME2yPE4xQTB3IN88US=> M3rWe3NCVkeHUh?=
LS-123 M4no[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\FTWM2OD1{OD6xNlYzKM7:TR?= NYK0bYZSW0GQR1XS
U031 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjoTWM2OD1{OD6yOVIh|ryP MYnTRW5ITVJ?
NCI-H1792 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\hNWlEPTB;MkiuOFczOSEQvF2= NWDUO|ZMW0GQR1XS
NCI-H2087 NUS1XXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe3bG1qUUN3ME2yPE44PTV{IN88US=> NXT3PVI{W0GQR1XS
NCI-H2342 NIL6d3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPxTWM2OD1{OT61NlA5KM7:TR?= NFvwfJNUSU6JRWK=
SW626 M1y0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXifmtKSzVyPUK5Mlc2PiEQvF2= NVy2TFE5W0GQR1XS
LB2518-MEL Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvSTWM2OD1{OT64NVUh|ryP NHTDN5lUSU6JRWK=
RXF393 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LN[mlEPTB;M{CuNFk2OiEQvF2= NFqwU3pUSU6JRWK=
LC4-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDJW3pIUUN3ME2zNE4{ODl{IN88US=> M{P5O3NCVkeHUh?=
NCI-H1694 M3TzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEflU5hKSzVyPUOwMlY3OjRizszN MnH3V2FPT0WU
K5 NX2yT2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNyLkm3NFIh|ryP MXHTRW5ITVJ?
HDLM-2 NHTFU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTJTWM2OD1|MD65O|I2KM7:TR?= NH\WTXZUSU6JRWK=
BCPAP NHPYVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXe2lEPTB;M{GuPFM4QSEQvF2= MYjTRW5ITVJ?
BC-3 M{PzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf5OJNKSzVyPUOyMlE1ODNizszN MUHTRW5ITVJ?
LB996-RCC NVqxWmV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN{LkKzOVgh|ryP NXXFSIlLW0GQR1XS
NCI-H2009 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN{LkS5PFEh|ryP MXvTRW5ITVJ?
HTC-C3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K2RWlEPTB;M{OuO|UyQSEQvF2= NF\xTWZUSU6JRWK=
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELsOGJKSzVyPUO0MlQ1ODdizszN MmXkV2FPT0WU
CCRF-CEM M1:1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vtNmlEPTB;M{SuOVcyPSEQvF2= NF\RZWpUSU6JRWK=
AN3-CA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrlTWM2OD1|NT6wOVY5KM7:TR?= MnPIV2FPT0WU
NCI-H1734 NYDk[pJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli0TWM2OD1|NT6yOVYyKM7:TR?= MVXTRW5ITVJ?
Ca-Ski NFXDSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTPSpg{UUN3ME2zOU41OTBzIN88US=> NWj3VHBWW0GQR1XS
U-266 NHLwfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnFbG1KSzVyPUO1MlYyOTRizszN M{HqNnNCVkeHUh?=
SBC-5 NHjt[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN3Lke3PFEh|ryP NVnzd5J5W0GQR1XS
GT3TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN5LkGxOUDPxE1? MkjYV2FPT0WU
MDA-MB-175-VII NFTwUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN5LkKyOFgh|ryP M375[3NCVkeHUh?=
PFSK-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHXfIxKSzVyPUO3MlI1OzVizszN NGPicpFUSU6JRWK=
IMR-5 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXQOm9KSzVyPUO3MlI1QDdizszN NF\DcJpUSU6JRWK=
Daudi MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN5LkO1PVch|ryP M2q0fXNCVkeHUh?=
A498 NXHpUnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN5LkeyNVgh|ryP MX7TRW5ITVJ?
SCC-4 NFTUS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnie2xKSzVyPUO3Mlc5PDNizszN M2q2bXNCVkeHUh?=
COLO-680N NIS0PGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DWSGlEPTB;M{iuNlg5PSEQvF2= NW\ieGhUW0GQR1XS
SK-MES-1 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN6LkOyNVUh|ryP NF2yfGRUSU6JRWK=
SR M4DofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLRU4xKSzVyPUO4MlU1QTVizszN M{DE[nNCVkeHUh?=
LNCaP-Clone-FGC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfTTWVKSzVyPUO4MlU3OzdizszN NV7JWWlnW0GQR1XS
SK-HEP-1 NGLURlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny5TWM2OD1|OD63PFIzKM7:TR?= NIXwSIpUSU6JRWK=
BPH-1 M3ixWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;GRWlEPTB;M{iuPFMzQSEQvF2= MUnTRW5ITVJ?
NCI-H1755 NWLHfW9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDseplKSzVyPUO5MlU5OTdizszN NVLUZ5BsW0GQR1XS
LXF-289 M1HSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly5TWM2OD1|OT64NFg1KM7:TR?= M4XV[HNCVkeHUh?=
SW1088 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPlTWM2OD12MD6yNVA4KM7:TR?= NIXxdZpUSU6JRWK=
MOLT-4 NWP1WI16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnwblJnUUN3ME20NE4zQTBzIN88US=> Moj3V2FPT0WU
AsPC-1 M3ywN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrqU2pKSzVyPUSwMlQ2QDNizszN NGfEc25USU6JRWK=
HOP-62 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PVUWlEPTB;NECuOlU3QCEQvF2= M2P0RXNCVkeHUh?=
A172 NHfxOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojiTWM2OD12MD64OVEyKM7:TR?= M4XTWHNCVkeHUh?=
SN12C M2LKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\rcYNEUUN3ME20NE46Ozh3IN88US=> Mlr6V2FPT0WU
MDA-MB-231 M{O1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P2R2lEPTB;NECuPVg6QCEQvF2= MWjTRW5ITVJ?
RPMI-2650 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjWTWM2OD12MT6xOVk{KM7:TR?= MXnTRW5ITVJ?
KYSE-140 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLhTWM2OD12MT64NVI{KM7:TR?= Ml:wV2FPT0WU
KINGS-1 NV;Y[WVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnHfVRrUUN3ME20Nk41Pjl5IN88US=> MXPTRW5ITVJ?
HSC-3 NF65PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n5T2lEPTB;NEKuOlY3OSEQvF2= MorBV2FPT0WU
PC-14 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR|LkG4PFIh|ryP MlLaV2FPT0WU
COR-L105 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTR|Lk[1NFIh|ryP MoXLV2FPT0WU
BE-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTR2LkKzO|Eh|ryP MkLJV2FPT0WU
NCI-H661 NVPHPWpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPZmlEPTB;NESuNlk2QCEQvF2= NYrRem9IW0GQR1XS
IST-MEL1 NVzpO20yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR2LkO1PVkh|ryP NVfrU2cxW0GQR1XS
HCC1806 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\pTWM2OD12ND61PFc{KM7:TR?= MV;TRW5ITVJ?
COLO-800 NUHKelk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljkTWM2OD12ND64OFU{KM7:TR?= MWLTRW5ITVJ?
IST-SL2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR3LkGyOFch|ryP MVXTRW5ITVJ?
8305C MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR3LkOwPUDPxE1? MkT0V2FPT0WU
UACC-62 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR4LkK4O|Uh|ryP Mk\HV2FPT0WU
COR-L23 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2xTWM2OD12Nz6xPVkh|ryP NIPCVmlUSU6JRWK=
EFE-184 NWjyfmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR5LkO4PEDPxE1? NVqxNHZPW0GQR1XS
DMS-114 NXn1VXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO5TWM2OD12Nz60NVQ6KM7:TR?= NFzhd4lUSU6JRWK=
KYSE-520 NHH4NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrTe2tOUUN3ME20PE42OzF3IN88US=> M3y0T3NCVkeHUh?=
SNG-M NVzSPFhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7veWlKSzVyPUS5MlQ{PCEQvF2= NHjH[FdUSU6JRWK=
A2058 M4\rVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR7LkS4PFUh|ryP MorXV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID